Viewing Study NCT01283516

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 11:50 AM
Ignite Modification Date: 2025-12-26 @ 11:50 AM
Study NCT ID: NCT01283516
Status: COMPLETED
Last Update Posted: 2019-03-15
First Post: 2011-01-24
Is NOT Gene Therapy: False
Has Adverse Events: True
Brief Title: A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Tumors Characterized by Genetic Abnormalities of ALK View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ALK inhibitor, View
None NSCLC, View
None LDK378, View
None ceritinib, View
None genetic abnormalities View